Second line chemotherapy for metastatic colorectal carcinoma

1996 ◽  
Author(s):  
V Gebbia ◽  
A Testa ◽  
G Cannata ◽  
M Tirrito ◽  
A Longo ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Second Line ◽  
Metastatic Colorectal Carcinoma ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy

2015 ◽  
Vol 24 (3) ◽  
pp. 379-382
Author(s):  
Tadahisa Inoue ◽  
Hitoshi Sano ◽  
Takashi Mizushima ◽  
Hirotada Nishie ◽  
Hiroyasu Iwasaki ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Distant Metastases ◽  
Salvage Chemotherapy ◽  
Second Line ◽  
Effective Treatment Option ◽  
Second Line Chemotherapy ◽  
Best Response ◽  
Long Term Effect ◽  
Line Chemotherapy

We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.

FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

2020 ◽  
Author(s):  
Angela Lamarca ◽  
Daniel Palmer ◽  
Harpreet Wasan ◽  
Paul J. Ross ◽  
Yuk Ting Ma ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Tract Cancer ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document